• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物开发者的数据管理 101:一探幕后。

Data Management 101 for drug developers: A peek behind the curtain.

机构信息

EpicentRx, Torrey Pines, California, USA.

Clinical Trial Innovations, Mountain View, California, USA.

出版信息

Clin Transl Sci. 2023 Sep;16(9):1497-1509. doi: 10.1111/cts.13582. Epub 2023 Jul 6.

DOI:10.1111/cts.13582
PMID:37382299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10499417/
Abstract

In drug development a frequently used phrase is "data-driven". Just as high-test gas fuels a car, so drug development "runs on" high-quality data; hence, good data management practices, which involve case report form design, data entry, data capture, data validation, medical coding, database closure, and database locking, are critically important. This review covers the essentials of clinical data management (CDM) for the United States. It is intended to demystify CDM, which means nothing more esoteric than the collection, organization, maintenance, and analysis of data for clinical trials. The review is written with those who are new to drug development in mind and assumes only a passing familiarity with the terms and concepts that are introduced. However, its relevance may also extend to experienced professionals that feel the need to brush up on the basics. For added color and context, the review includes real-world examples with RRx-001, a new molecular entity in phase III and with fast-track status in head and neck cancer, and AdAPT-001, an oncolytic adenovirus armed with a transforming growth factor-beta (TGF-β) trap in a phase I/II clinical trial with which the authors, as employees of the biopharmaceutical company, EpicentRx, are closely involved. An alphabetized glossary of key terms and acronyms used throughout this review is also included for easy reference.

摘要

在药物研发中,一个经常使用的短语是“数据驱动”。就像高辛烷值的汽油为汽车提供动力一样,药物研发也“依赖”高质量的数据;因此,良好的数据管理实践,包括病例报告表设计、数据录入、数据采集、数据验证、医学编码、数据库关闭和数据库锁定,至关重要。本篇综述涵盖了美国临床数据管理(CDM)的要点。它旨在揭开 CDM 的神秘面纱,CDM 只不过是为临床试验收集、组织、维护和分析数据。本篇综述是为那些刚接触药物研发的人写的,仅假设对所介绍的术语和概念有一定的了解。然而,它也可能与有经验的专业人士相关,这些人可能觉得有必要复习一下基础知识。为了增加趣味性和背景知识,本篇综述包括了 RRx-001(一种处于 III 期并具有头颈部癌症快速通道地位的新型分子实体)和 AdAPT-001(一种携带转化生长因子-β(TGF-β)陷阱的溶瘤腺病毒,正在进行 I/II 期临床试验)的真实案例,作者作为生物制药公司 EpicentRx 的员工,与这两项研究密切相关。本篇综述还包含了贯穿全文的关键词和缩略语的字母顺序列表,方便查阅。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/1dc4a7afaa5e/CTS-16-1497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/67e0de9bfbce/CTS-16-1497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/5d38b6be73e1/CTS-16-1497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/c0f9440c3690/CTS-16-1497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/b8a2ed8cc0e6/CTS-16-1497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/1dc4a7afaa5e/CTS-16-1497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/67e0de9bfbce/CTS-16-1497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/5d38b6be73e1/CTS-16-1497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/c0f9440c3690/CTS-16-1497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/b8a2ed8cc0e6/CTS-16-1497-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10499417/1dc4a7afaa5e/CTS-16-1497-g004.jpg

相似文献

1
Data Management 101 for drug developers: A peek behind the curtain.药物开发者的数据管理 101:一探幕后。
Clin Transl Sci. 2023 Sep;16(9):1497-1509. doi: 10.1111/cts.13582. Epub 2023 Jul 6.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Data management in clinical research: An overview.临床研究中的数据管理:概述。
Indian J Pharmacol. 2012 Mar;44(2):168-72. doi: 10.4103/0253-7613.93842.
5
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.INGN 201:腺病毒载体p53、Ad5CMV-p53、腺病毒p53、p53基因疗法——英特洛根公司,RPR/INGN 201。
Drugs R D. 2007;8(3):176-87. doi: 10.2165/00126839-200708030-00005.
6
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树:影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
7
Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.博来霉素——电脉冲给药:电穿孔疗法——博来霉素——基因电子公司;MedPulser——博来霉素——基因电子公司
Drugs R D. 2004;5(5):293-6. doi: 10.2165/00126839-200405050-00005.
8
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.厄洛替尼:CP 358774、NSC 718781、OSI 774、R 1415。
Drugs R D. 2003;4(4):243-8. doi: 10.2165/00126839-200304040-00006.
9
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.综合护理路径在医疗环境中对成人和儿童的有效性:一项系统评价。
JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001.
10
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.急性缺血性脑卒中动脉内脑溶栓的试验设计与报告标准。
Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.

本文引用的文献

1
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.RRx-001:一种嵌合型三重作用的NLRP3抑制剂、Nrf2诱导剂和一氧化氮超激动剂。
Front Oncol. 2023 May 29;13:1204143. doi: 10.3389/fonc.2023.1204143. eCollection 2023.
2
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).RRx-001 联合纳武利尤单抗治疗晚期转移性癌症患者的 1 期初步研究(PRIMETIME)。
Front Immunol. 2023 Mar 7;14:1104753. doi: 10.3389/fimmu.2023.1104753. eCollection 2023.
3
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
RRx-001 综述:一种晚期多适应症 NLRP3 激活和慢性炎症抑制剂。
Drugs. 2023 Apr;83(5):389-402. doi: 10.1007/s40265-023-01838-z. Epub 2023 Mar 15.
4
Profile EpicentRx, Inc.EpicentRx公司简介
Hum Vaccin Immunother. 2023 Dec 31;19(1):2184963. doi: 10.1080/21645515.2023.2184963. Epub 2023 Mar 13.
5
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy.PREVLAR:一项评估 RRx-001 减轻头颈部放化疗患者口腔黏膜炎的安全性和有效性的 2a 期随机临床试验。
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):551-559. doi: 10.1016/j.ijrobp.2022.12.031. Epub 2023 Jan 14.
6
Patent and Marketing Exclusivities 101 for Drug Developers.药物开发者专利和营销专有权 101。
Recent Pat Biotechnol. 2023;17(3):257-270. doi: 10.2174/1872208317666230111105223.
7
Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.两名新冠肺炎呼吸衰竭患者在给予抗癌小分子药物RRx-001后的临床病程
Int Med Case Rep J. 2022 Dec 15;15:735-738. doi: 10.2147/IMCRJ.S389690. eCollection 2022.
8
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.ROCKET:一项II期随机、活性对照、多中心试验,旨在评估RRx-001联合伊立替康与单药瑞戈非尼在三线/四线结直肠癌治疗中的安全性和疗效。
Clin Colorectal Cancer. 2023 Mar;22(1):92-99. doi: 10.1016/j.clcc.2022.11.003. Epub 2022 Dec 2.
9
RRx-001 and the "Right stuff": Protection and treatment in outer space.RRx-001 和“必备要素”:外层空间的防护与治疗。
Life Sci Space Res (Amst). 2022 Nov;35:69-75. doi: 10.1016/j.lssr.2022.05.001. Epub 2022 May 12.
10
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats.大鼠直接静脉注射 RRx-001 引起的浅表静脉相关性炎症。
Int J Med Sci. 2022 Sep 21;19(11):1628-1630. doi: 10.7150/ijms.76615. eCollection 2022.